

Why Australia for your Clinical Development Strategy

Australia offers the essential elements for success to any Emerging Biopharma (EBP): Speed, financial benefits, globally accepted quality data




* CTN: Clinical Trial Notification, IND: Investigational New Drug, IB: Investigator Brochure, PICF: Participant Information and Consent Form, FDA: Food and Drug Administration, EMA: European Medicines Agency, KOL: Key Opinion Leader

Australia is a leading global destination for early phase trials

International investment in early phase trials


One-thirds of public early phase trials involved investment from **sponsors in Australia**.



Data showed continued strength of Australia in **FIH* and Phase I trials.**

Distribution of trials

by phases



Source: Bellbery Clinical Trial Report 2022 Dataset; Research approved by Bellberry HRECs (2022 calendar year) and NSW Early Phase Clinical Trial (EPCT) Framework (2022 calendar year).

* FIH: First In Human



towards sponsors adding POC* cohorts. Data from these POC studies can help inform go/no-go decision, helping EBPs avoid spending time and money on targets/molecules unlikely to succeed. This is a practice that Australia sites are familiar with and do very well.

* POC: Proof Of Concept

CONTACT US IQVIA Biotech in Australia URL: https://www.iqvia.com/locations/australia-and-new-zealand